Northern Trust
CTKB icon

Northern Trust’s Cytek Biosciences CTKB Stock Holding History

Northern Trust’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.44M Sell
1,003,294
-1,899
-0.2% -$8.11K ﹤0.01% 2685
2026
Q1 		$4.39M Buy
1,005,193
+47,599
+5% +$225K ﹤0.01% 2528
2025
Q4 		$4.84M Sell
957,594
-55,989
-6% -$260K ﹤0.01% 2495
2025
Q3 		$3.52M Sell
1,013,583
-82,411
-8% -$309K ﹤0.01% 2700
2025
Q2 		$3.73M Sell
1,095,994
-55,573
-5% -$185K ﹤0.01% 2637
2025
Q1 		$4.62M Sell
1,151,567
-36,764
-3% -$191K ﹤0.01% 2457
2024
Q4 		$7.71M Buy
1,188,331
+121,268
+11% +$722K ﹤0.01% 2274
2024
Q3 		$5.91M Sell
1,067,063
-18,324
-2% -$104K ﹤0.01% 2383
2024
Q2 		$6.06M Sell
1,085,387
-45,235
-4% -$272K ﹤0.01% 2284
2024
Q1 		$7.59M Sell
1,130,622
-60,002
-5% -$475K ﹤0.01% 2223
2023
Q4 		$10.9M Buy
1,190,624
+47,649
+4% +$300K ﹤0.01% 2005
2023
Q3 		$6.31M Buy
1,142,975
+68,327
+6% +$548K ﹤0.01% 2298
2023
Q2 		$9.18M Buy
1,074,648
+106,758
+11% +$958K ﹤0.01% 2127
2023
Q1 		$8.89M Buy
967,890
+27,943
+3% +$301K ﹤0.01% 2098
2022
Q4 		$9.6M Buy
939,947
+18,278
+2% +$246K ﹤0.01% 2041
2022
Q3 		$13.6M Buy
921,669
+93,053
+11% +$1.21M ﹤0.01% 1763
2022
Q2 		$8.89M Buy
828,616
+121,153
+17% +$1.21M ﹤0.01% 2118
2022
Q1 		$7.63M Buy
707,463
+547,658
+343% +$7.4M ﹤0.01% 2319
2021
Q4 		$2.61M Buy
159,805
+15,946
+11% +$334K ﹤0.01% 3095
2021
Q3 		$3.08M Buy
+143,859
New +$3.38M ﹤0.01% 3044

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust's CTKB Position: Q2 2026 in Review

Northern Trust reduced its Cytek Biosciences (CTKB) stake by 0.19% in Q2 2026, selling an estimated $8.11K and leaving 1,003,294 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

Northern Trust first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $13.6M in Q3 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Northern Trust held 1,003,294 shares of Cytek Biosciences worth $4.44M as of Q2 2026.
  • Northern Trust sold 1,899 Cytek Biosciences shares in Q2 2026, an estimated $8.11K.
  • Cytek Biosciences made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2685 holding.
  • Northern Trust first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Northern Trust's Cytek Biosciences position peaked at $13.6M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.